Lannett Co (Lannett Co) Growth Rank : 0 (As of Apr. 27, 2024)

View and export this data going back to 1994. Start your Free Trial

What is Lannett Co Growth Rank?

Lannett Co has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Lannett Co Growth Rank Related Terms

Thank you for viewing the detailed overview of Lannett Co's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Lannett Co (Lannett Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lannett Co Inc (OTCPK:LCINQ) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

1150 Northbrook Drive, Suite 155, Trevose, PA, USA, 19053

Website

https://www.lannett.com

Lannett Co Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products. It offers solid oral, extended-release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. In addition, the company also provides its products for various medical indications comprising glaucoma, gastrointestinal, migraine, obesity, respiratory, and others. It operates in the segment of generic pharmaceuticals. Its customers include generic pharmaceutical distributors, drug wholesalers, chain drug stores, private label distributors, mail-order pharmacies, and others.

Executives

John C Chapman	director	9000 STATE ROAD, PHILADELPHIA PA 19136
Timothy C Crew	officer: Chief Executive Officer	9000 STATE ROAD, PHILADELPHIA PA 19136
Patrick G Lepore	director	17-17 ROUTE 208 N, FAIRLAWN NJ 07410
Melissa Rewolinski	director	9000 STATE ROAD, PHILADELPHIA PA 19136
Jeffrey Farber	officer: Secretary
Samuel H Israel	officer: Chief Legal Officer	9000 STATE ROAD, PHILADELPHIA PA 19136
John Abt	officer: Vice President of Quality	9000 STATE ROAD, PHILADELPHIA PA 19136
John Kozlowski	officer: Chief Operating Officer	9000 STATE ROAD, PHILADELPHIA PA 19136
David A Drabik	director	9000 STATE RD, PHILADELPHIA PA 19136
Paul Taveira	director	9000 STATE ROAD, PHILADELPHIA PA 19136
Albert Iii Paonessa	director	9852 NW 2ND COURT, PLANTATION FL 33324
Kevin Smith	other: Vice President
Maureen Cavanaugh	officer: Senior Vice President and CCOO	9000 STATE ROAD, PHILADELPHIA PA 19136
David Farber	officer: Treasurer
Arthur P Bedrosian	officer: President	P O BOX D 1400, POMONA NY 10970